AstraZeneca will receive $700 million for the sale, settled in cash. Following this transaction, Royalty Pharma will receive royalty revenue formerly payable to Cambridge Antibody Technology based on
Drugs granted priority status can be reviewed in six months, rather than the standard ten. Abbot said that the FDA based its decision on the results of a
The vaccine will be covered for individuals 60 years of age and older whose benefit plans provide coverage for vaccines. WellPoint already provides benefits for Zostavax based on
The Junovan new drug submission includes efficacy and safety data from a phase III trial of the bone cancer known as osteosarcoma. The trial was conducted by the
In Canada, a priority review is generally reserved for drugs intended to treat serious or life threatening conditions. Based on clinical trial data, Lucentis has the potential to
Ono has obtained exclusive rights to develop and commercialize RC-1291 in Japan, Korea and Taiwan under this agreement. Ono will pay Sapphire upfront and milestone payments as well
The new class of drugs that target the enzyme Aurora B could be an alternative to current treatments as they seem to be less toxic and are still
The phase II trial evaluates Cloretazine in two separate subpopulations of small cell lung cancer, sensitive relapsed disease and refractory disease. Sensitive relapsed disease is defined as relapse
“We expect to initiate phase III trials of LymphoStat-B before the end of 2006, and we look forward to moving ahead with site activation and patient enrollment,” said
Velcade is a leading cancer therapeutic used to treat patients with relapsed multiple myeloma. Under the terms of the agreement, Ortho Biotech will join Millennium in the first
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.